selpercatinib
FDA Fully Approves Retevmo for RET Fusion-Positive Medullary Thyroid Cancer
The FDA has granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric ...
SEPTEMBER 30, 2024
FDA Grants Traditional Approval to Retevmo for RET Fusion–Positive Thyroid Cancer
The FDA has granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric ...
JUNE 14, 2024
Retevmo Approved for Pediatric Patients with RET-altered Metastatic Thyroid Cancer or Solid Tumors
The FDA has granted accelerated approval to selpercatinib (Retevmo, Lilly.
MAY 30, 2024
FDA Approves Retevmo for Locally Advanced or Metastatic RET Fusion-positive Solid Tumors
The FDA has granted accelerated approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult patients with ...
SEPTEMBER 22, 2022
Retevmo Approved for RET-Driven NSCLC and Thyroid Cancers
The FDA granted accelerated approval to the selective RET kinase inhibitor selpercatinib (Retevmo, Lilly) for ...
MAY 14, 2020
